CTLA4 and neoplasm: By competing with CD28 for binding of the costimulatory molecules CD80/86 expressed by antigen presenting cells, CTLA-4 was shown to reduce T cell activation and blockade of this receptor led to increased T cell activation and, critically, tumour regression in a mouse model of melanoma [11].